CoreBone

What CoreBone does

CoreBone is an Israeli privately held biotechnology company headquartered in Misgav, Israel, that cultivates coral in a closed, controlled aquarium system and sells the resulting material as a bioactive bone graft substitute. The company's core technology uses proprietary lab-formulated seawater, exclusive coral propagation strains, and a closed aquaculture process to produce consistent, sustainable coral scaffolds that mimic the composition and porous structure of human bone, avoiding the disease-transmission and ethical risks of bovine, human, and wild-harvested marine grafts. CoreBone's product portfolio includes three dental bone graft SKUs differentiated by particle size (CoreBone 500 at 250-600 microns, CoreBone 1000 at 600-1000 microns, and CoreBone 2000 at 1000-2000 microns), each available in small unit volumes (0.25-2.0 cc), plus a CoreInject prefilled syringe delivery system in development.

The company generates revenue through direct sales of these hardware products to dental professionals — including oral surgeons, periodontists, implantologists, and dental surgeons — and is expanding its addressable market with CoreTlage, a patented cartilage regeneration platform built on the same cultivated coral platform that has completed preclinical studies and is entering First In Man clinical trials for orthopedic indications. The go-to-market is sales-led and direct, leveraging scientific publications, a corporate website (with a Chinese-language version at corebone-cn.com), LinkedIn, WhatsApp, and WeChat, supported by clinical case documentation and endorsements from dental and orthopedic key opinion leaders. CoreBone reports over 10,000 successful clinical cases across EMEA and Southeast Asia since commercial launch in 2017, supplemented by a 168-case multicenter clinical study, and operates an additional office on Guangzhou International Bio Island in China. The company is led by co-founder and CEO Ohad Schwartz and has raised $3.7M to date (October 2021 round led by GIBF, with Agriline and Trendlines Group).

Name

CoreBone

Legal name

COREBONE

Website

https://core-bone.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

CoreBone is an Israeli biotech company that cultivates coral in closed aquaculture systems and sells it as a bioactive bone graft substitute for dental and orthopedic applications, with a cartilage regeneration platform in clinical development.

Ownership category

akta.pro rank

Product category

Bone Graft Substitutes and Dental Regenerative Materials

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Dental Equipment & Supplies (3843)

akta.pro industry

PRIMARYHLAHAEAG

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

SECONDARYHLAAAGAB

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLAAAGAH

Cartilage, Bone & Musculoskeletal Regeneration

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYHLABAEAB

Dental Implant Surgery & Bone Grafting

Healthcare & Life Sciences/Dental Care Services/Oral & Maxillofacial Surgery

Keywords

• Bone graft substitutes
• Coral-based implants
• Tissue engineering materials
• Dental bone regeneration
• Cartilage repair scaffolds

Headquarters

HQ city

Herzliya

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Coral Bone Graft Products: Sale of cultivated coral-based bone graft materials for dental and orthopedic applications. Products include CoreBone 500, CoreBone 1000, CoreBone 2000, and CoreInject prefilled syringes. Revenue generated from product sales to dental and orthopedic professionals.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

CoreBone manufactures and sells cultivated coral-based bone graft substitute materials for dental and orthopedic applications. The product line includes CoreBone 500, 1000, and 2000 granular dental bone grafts differentiated by particle size, the CoreInject prefilled syringe delivery system, and the CoreTlage cartilage regeneration platform for orthopedic use. Corals are cultivated in a proprietary closed-system aquarium and used as bioactive scaffolds that integrate with natural bone and cartilage, providing a safe alternative to bovine, human, and marine-harvested graft materials.

Product overview

CoreBone offers a portfolio of coral-based tissue engineering products for bone and cartilage regeneration. The product line consists of dental bone grafts (CoreBone 500, CoreBone 1000, CoreBone 2000) differentiated by particle size for various oral bone defect applications, supplemented by the CoreInject prefilled syringe delivery system. The company also developed CoreTlage, a breakthrough cartilage regeneration platform leveraging the same cultivated coral technology for orthopedic applications. CoreBone's coral cultivation technology provides sustainable, natural scaffolds for tissue engineering, distinguishing it from bovine, human, and marine-harvested bone graft materials.

Differentiator

Problem solved

Functional benefit

Brands

• CoreTlage: Coral-based articular cartilage regeneration platform that regenerates hyaline-like cartilage, targeting orthopedic applications.

Products and services

• CoreBone 500 Granular cultivated coral-based dental bone graft with particle size 250-600 microns, available in 0.25, 0.5, and 1.0 cc volumes, designed for smaller oral bone defects, alveolar bone preservation, and peri-implant bone preservation for immediate implantation. Used by dentists, periodontists, and oral surgeons.
• CoreBone 1000 Granular cultivated coral-based dental bone graft with particle size 600-1000 microns, available in 0.5, 1.0, and 2.0 cc volumes, designed for alveolar bone preservation for moderate oral bone defects. Used by dental professionals.
• CoreBone 2000 Granular cultivated coral-based dental bone graft with particle size 1000-2000 microns, available in 0.5, 1.0, and 2.0 cc volumes, designed for larger oral bone defects. Used by dental professionals.
• CoreInject Prefilled syringe delivery system preloaded with CoreBone 500/1000 bone grafts, providing easier and more convenient application and helping reduce pollution risk during dental bone grafting procedures. For dental professionals.
• CoreTlage Patented coral-based articular cartilage regeneration platform that leverages CoreBone's sustainable coral cultivation technology to regenerate hyaline-like cartilage for articular cartilage repair in orthopedic applications such as knee and joint injuries. Targets orthopedic surgeons and sports medicine specialists.

Quantifiable outcome

• Over 10,000 successful clinical cases worldwide with very positive results
• +4 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Geistlich Pharma (Bio-Oss): Geistlich Pharma is the global market leader in dental bone grafting via its Bio-Oss bovine-derived bone graft. It is CoreBone's primary direct competitor, offering the incumbent alternative that CoreBone explicitly positions against in dental applications.
• Botiss Biomaterials: Botiss is a European specialist in dental bone graft substitutes, membranes and soft-tissue products for implantology and periodontology. It is highly comparable to CoreBone as a focused dental regeneration competitor with overlapping SKU portfolios (bone graft granules, particulate allografts and xenografts).
• LifeNet Health: LifeNet Health is a major allograft tissue bank offering bone graft substitutes and regenerative implants for dental, orthopedic and spine applications. It is a direct peer as an established bone graft substitute provider addressing many of the same clinical use cases as CoreBone's dental franchise.
• NovaBone Products: NovaBone is a U.S. company specializing in synthetic (bioactive glass) bone graft substitutes used in dental and orthopedic surgery. It competes with CoreBone in both dental bone grafting and bone regeneration, sharing the mission of providing an alternative to autograft and bovine materials.
• RTI Surgical: RTI Surgical processes allograft and xenograft bone graft substitutes for dental, spine and orthopedic surgeons. It is comparable to CoreBone as a bone graft substitute specialist with shared clinical customers and overlapping indications, including cartilage and bone regeneration.

Broad incumbents

• Medtronic (Orthobiologics / Infuse): Medtronic's Spine division includes the Infuse Bone Graft and broader orthobiologics portfolio for spinal fusion, orthopedic trauma and dental regeneration. It is a broad incumbent whose regenerative medicine offerings compete with CoreBone's coral-based grafts in the bone regeneration space.
• Zimmer Biomet: Zimmer Biomet offers dental regenerative products (e.g., RegenerOss), bone graft substitutes and orthobiologics through its dental and orthopedic franchises. It is a broad incumbent in the same bone graft substitute category as CoreBone with a vastly larger sales infrastructure.
• Straumann: Straumann is a global dental implant leader with a growing regenerative portfolio (botiss acquired in 2023) covering bone graft substitutes, membranes and digital workflows. It is a broad incumbent competing with CoreBone for dental implantology bone augmentation cases.
• Smith+Nephew: Smith+Nephew's Global Orthopedics business includes regenerative medicine products (e.g., REGENETEN, BIOINDUCT) for cartilage and bone repair. It is a broad incumbent with adjacent cartilage regeneration efforts relevant to CoreTlage.

Emerging players

• BoneSupport AB: BoneSupport develops CERAMENT, a synthetic injectable bone graft substitute for orthopedic trauma and bone infection. It is an emerging peer with overlapping orthopedic bone regeneration applications, focused on injectable formats analogous to CoreBone's planned CoreInject prefilled syringe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/17882021

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoreBone